Table 1.
Clinical characteristicof 252 CKD patients.
| All patients (n = 252) | |
|---|---|
| Male (%) | 59.1 |
| Age (years) | 67 (60–75) |
| Diabetes (%) | 35.7 |
| Smoking (%) | 37.9 |
| Systolic BP (mmHg) | 130 (122–142) |
| BMI (kg/m2) | 22.3 (20.2–24.7) |
| CKD grade (%) | |
| G3a | 25.4 |
| G3b | 14.7 |
| G4 | 35.7 |
| G5 | 24.2 |
| Plasma NGAL (ng/mL) | 105 (60–194) |
| Urinary NGAL (μg/gCr) | 65 (15–235) |
| BNP (pg/mL) | 30 (17–71) |
| eGFR (mL/min/1.73 m2) | 25.1 (15.2–38.5) |
| Hemoglobin (g/dL) | 11.3 (9.8–12.7) |
| hsCRP (mg/L) | 0.6 (0.2–1.5) |
| UACR (mg/gCr) | 338 (102–1321) |
| TG (mg/dL) | 137 (103–193) |
| LDL-C (mg/dL) | 109 (87–129) |
| HDL-C (mg/dL) | 54 (44–68) |
| ECGa | |
| LVH (%) | 6.1 |
| ST-T change (%) | 9.8 |
| EF (%) by UCGb | 60.0 (57.0–64.0) |
| ARB or ACEi (%) | 71.0 |
| Statins (%) | 29.8 |
a n = 194; b n = 151.
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; BMI, body mass index; BNP, B-type natriuretic peptide; ECG, electrocardiogram; CKD, chronic kidney disease; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein-cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein-cholesterol; LVH, left ventricular hypertrophy; NGAL, neutrophil gelatinase-associated lipocalin; TG, triglyceride; UACR, urinary albumin creatinine ratio; UCG, ultracardiography.